Anticalins: inhalable biologicals for severe asthma

Anticalins：治疗严重哮喘的吸入生物制剂

• 批准号: nhmrc : GNT1093388
• 负责人: A/Pr Louis Irving
• 金额: $ 37.61万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: Development Grants
• 财政年份: 2015
• 资助国家: 澳大利亚
• 起止时间: 2015-01-01 至 2017-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/anticalins-inhalable-biologicals-severe-asthma/1345918
• 关键词: Anticalins; inhalable; biologicals; severe; asthma

This grant aims to develop a new class of medicines called 'anticalins'. Anticalins behave like a successful class of medicines called monoclonal antibodies (mAbs). MAbs are too fragile and large to be inhaled to treat lung disease but anticalins are small and robust. We will be developing an anticalin (PRS-060) which blocks damaging immune reactions in severe asthma. By inhaling PRS-060 we hope to make a new and clinically useful medicine for a common form of poorly-controlled severe asthma.

这笔赠款旨在开发一种名为“anticalins”的新药。Anticalins的作用类似于一类成功的药物，称为单克隆抗体（mAb）。单克隆抗体太脆弱和大，不能吸入治疗肺部疾病，但anticalins小而强大。我们将开发一种抗运载蛋白（PRS-060），它可以阻止严重哮喘患者的破坏性免疫反应。通过吸入PRS-060，我们希望为一种常见的控制不良的严重哮喘提供一种新的临床有用的药物。